Sales of Spectrum's drug Fusilev for patients with metastatic colorectal cancer remain strong heading into the remainder of 2014, said the company's CEO Rajesh Shrotriya. Total revenue was $46.9 million in Spectrum's second quarter, up 41% from the prior year. Fusilev accounted for $26.6 million of Spectrum's sales in the second quarter, or 56% of total revenue. Outside Fusilev, Shrotriya expects to make a Phase 3 Go/No-Go decision by the end of the year for SPI-2012, a long-acting GCSF drug which he believes could be a 'potential blockbuster'. Finally, Shrotriya said he is seeing a strong sales trajectory for Spectrum's drug Beleodaq for the treatment of patients suffering from peripheral T-cell lymphoma.

More from Video

10 Seconds to Genius: Lowe's New CEO Marvin Ellison

10 Seconds to Genius: Lowe's New CEO Marvin Ellison

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

NYSE's New President: On a Mission to Attract Talent to Wall St.

NYSE's New President: On a Mission to Attract Talent to Wall St.

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

10 Seconds To Genius: Facebook

10 Seconds To Genius: Facebook